CLASS II Drug recall · Reported 28 Nov 2018 · FDA Enforcement Report

GSMS Irbesartan Tablets, USP, 150 mg, (a) bottle recalled

Sciegen Pharmaceuticals is recalling GSMS Irbesartan Tablets, USP, 150 mg, (a) bottle (, distributed nationwide in the US. The recall was initiated on 29 Oct 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codes60429-641-90 Irbesartan 150mg Tablets, 90 Count Bottle B161003 Sep-19 B161004 Sep-19 B161006 Sep-19 B161007 Sep-19 B161008 Nov-19 B161009 Nov-19 B161010 Nov-19 C161001 Feb-20 C161003 May-20 60429-641-30 Irbesartan 150mg Tablets, 30 Count Bottle GS019526 Nov-19 GS020252 Nov-19 GS020958 Nov-19
Quantity recalled18,760 HDPE bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0271-2019
FDA event ID
81458
Recalling firm
Sciegen Pharmaceuticals, Hauppauge, NY
Classification
Class II
Status
Terminated
Recall initiated
29 Oct 2018
FDA classified
20 Nov 2018
Reported
28 Nov 2018
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Nitrosamine Impurity

Timeline

29 Oct 2018Recall initiated by company
20 Nov 2018Classified by FDA+22 days
28 Nov 2018Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (NDC 60429-641-90), Rx Only, Manufactured by ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Marketed by: GSMS Incorporated Camarillo, CA 93012 USA.

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Is GSMS Irbesartan Tablets, USP, 150 mg, (a) bottle ( recalled?

Yes. Sciegen Pharmaceuticals recalled GSMS Irbesartan Tablets, USP, 150 mg, (a) bottle ( on 29 Oct 2018. The recall is Class II and its status is Terminated. Recall number D-0271-2019.

Why was it recalled?

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Which lots are affected?

60429-641-90 Irbesartan 150mg Tablets, 90 Count Bottle B161003 Sep-19 B161004 Sep-19 B161006 Sep-19 B161007 Sep-19 B161008 Nov-19 B161009 Nov-19 B161010 Nov-19 C161001 Feb-20 C161003 May-20 60429-641-30 Irbesartan 150mg Tablets, 30 Count Bottle GS019526 Nov-19 GS020252 Nov-19 GS020958 Nov-19

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Sciegen Pharmaceuticals

All 7

Other Gsms irbesartan recalls

All 3